Modeling need-based resource allocation for global health financing — disease burden, income eligibility, and impact-per-dollar
Every allocation cycle begins with the most contested and consequential number in global health finance: how much disease burden does each country actually carry? The Global Fund and Gavi both anchor their formulas in Disability-Adjusted Life Years (DALYs) and disease-specific incidence/prevalence estimates, triangulated across WHO, UNAIDS, and national surveillance systems.
A DALY combines two components: Years of Life Lost (YLL) to premature mortality and Years Lived with Disability (YLD), weighted by a disability severity index for each health state. For HIV, TB, and malaria, national burden estimates are built from:
• Surveillance and case-notification data reported by national disease programs • Demographic and Health Surveys (DHS) and Malaria Indicator Surveys providing population-representative prevalence • UNAIDS Spectrum modeling for HIV incidence/prevalence, reconciling surveillance gaps with epidemiological models • WHO Global Tuberculosis Report estimates, which explicitly model underreporting in weak surveillance systems
Because raw case counts undercount true burden in health systems with limited diagnostic and reporting capacity, the Global Fund applies modeled estimates rather than raw notifications alone — a country with excellent surveillance and a country with poor surveillance but identical true burden should receive comparable allocations, not one penalized for reporting well.
HIV, TB, and malaria are allocated through disease-specific formulas that are then combined into a single country envelope, since a country like Nigeria carries significant burden across all three simultaneously while Ukraine's burden is concentrated in HIV and TB.
Each disease-specific model incorporates: • Absolute burden (total DALYs or deaths attributable to the disease nationally) • Burden intensity (prevalence or incidence rate, capturing how concentrated the epidemic is) • Trend direction (whether burden is rising or falling, informing whether current investment is working)
The combined country envelope is then passed into the allocation formula (Stage 2) alongside the income-eligibility factor, producing the funding split visualized in the simulation as differently sized flow streams from the pool to each country node.
The Global Fund allocation methodology combines disease burden (weighted roughly 70% of the formula) with an income-eligibility factor tied to World Bank income classification, producing a country-level funding envelope for the three-year cycle. Gavi applies a structurally similar logic — burden plus Gross National Income (GNI) per capita — for vaccine financing.
Country Envelope = f(Disease Burden) × g(Economic Capacity)
• Disease burden component: a country's share of total portfolio DALYs/incidence across HIV, TB, and malaria, adjusted for population size — this component alone drives roughly 70% of the variance in final allocations • Economic capacity component: a multiplier derived from World Bank income classification (low-income, lower-middle-income, upper-middle-income) and domestic health financing capacity — low-income countries receive a higher multiplier per unit of burden than upper-middle-income countries, which are expected to co-finance a larger share domestically • Qualitative adjustments: transition countries moving up income brackets receive tapered, not cliff-edge, reductions in eligibility to avoid destabilizing functioning programs
Gavi's parallel approach uses GNI per capita directly as the eligibility gate (historically around $1,730 per capita, adjusted periodically) combined with birth-cohort size and vaccine-preventable disease burden — the same conceptual architecture of burden × ability-to-pay, tuned for immunization rather than treatment programs.
The formula only distributes what has actually been raised. The Global Fund operates on three-year replenishment cycles, where donor governments, private foundations, and corporate partners pledge funding at a Replenishment Conference:
• 6th Replenishment (2019): $14.0 billion pledged for 2020–2022 • 7th Replenishment (2022, hosted by the United States): $15.7 billion raised for the 2023–2025 implementation period, against an $18 billion target — the allocation formula then apportions this realized total, not the aspirational target, meaning every cycle involves a scaling-down step applied uniformly across all country envelopes
This replenishment dependency is a structural feature the simulation's funding-pool node represents: the pool's total size is itself a political and fundraising outcome upstream of the technical allocation formula, and shortfalls against target compress every country's envelope proportionally.
An allocation envelope is not yet a program. Country Coordinating Mechanisms (CCMs) — the Global Fund's signature multi-stakeholder governance innovation — translate the funding envelope into a concrete, technically reviewed program before a single dollar disburses.
Every country receiving Global Fund financing must establish or maintain a CCM — a national committee that must include government ministries, civil society organizations, people living with the diseases being funded, the private sector, and technical/multilateral partners in the same room, with no single constituency holding a controlling majority.
The CCM's core functions: • Prioritize which interventions within the allocation envelope get funded — a country cannot fund everything within HIV, TB, and malaria simultaneously, so the CCM negotiates trade-offs between, for example, expanding antiretroviral coverage versus scaling up insecticide-treated bednet distribution • Nominate Principal Recipients (PRs) — the implementing entities (often a Ministry of Health plus one or two NGO/civil-society PRs) that will receive and account for grant funds • Provide local oversight throughout implementation, distinct from the Global Fund Secretariat's own oversight
This structure exists specifically to counter the historical failure mode of donor-driven health financing, where funding decisions made in Geneva or Washington poorly matched on-the-ground implementation realities.
The country's funding request is scored by an independent Technical Review Panel (TRP) — public health and finance experts unaffiliated with the country or the Global Fund Secretariat — against criteria including technical soundness, feasibility, sustainability, and value for money.
Requests that pass TRP review proceed to grant-making: detailed negotiation between the Secretariat and the nominated Principal Recipients over budgets, performance indicators, procurement plans (frequently routed through the Fund's Pooled Procurement Mechanism for medicines and health products to secure volume pricing), and risk-mitigation measures for countries with weaker financial management track records.
The entire path from allocation envelope to signed, disbursement-ready grant typically takes 6–9 months — a deliberate trade-off between speed and the due diligence needed to protect against the fiduciary risk of directing hundreds of millions of dollars through national systems of varying capacity.
Signed grants do not release as a single payment. Funds disburse in tranches tied to demonstrated progress against agreed indicators, giving the Global Fund a mechanism to course-correct, pause, or redirect funding mid-cycle rather than discovering a program failure only after the full grant has been spent.
A grant signed for a three-year, $200 million program does not transfer $200 million on day one. Instead, an initial tranche covers early implementation costs, with subsequent tranches released contingent on the Principal Recipient reporting progress against pre-agreed programmatic and financial indicators — number of patients on treatment, bednets distributed, TB cases notified and treated, alongside standard financial absorption and audit compliance.
This structure serves two purposes simultaneously: it limits the Fund's exposure to a single failing program (a stalled grant can be paused before the full envelope is lost), and it creates a continuous accountability rhythm that keeps implementing partners reporting on real outcomes rather than only at grant closeout.
Grant performance is rated on an A1–D scale by the Secretariat's Grant Management division; grants rated persistently in the lower bands (C or D, indicating poor performance or significant fiduciary concern) can have disbursement suspended pending a corrective action plan — the direct link into Stage 6's reallocation logic.
A country's "absorptive capacity" — its ability to actually spend allocated funds effectively through functioning procurement, health workforce, and financial management systems — is itself a factor the Fund monitors and, in the extreme, a reason allocation formulas cap country envelopes below pure burden-proportional levels.
A country with severe burden but very low absorptive capacity (weak procurement systems, limited health workforce, fragile financial oversight) may be unable to productively spend a burden-proportional allocation within the grant period — in these cases, the Fund pairs a smaller initial envelope with technical assistance investment aimed at building the systems needed to absorb larger allocations in future cycles, rather than disbursing funds a system cannot execute.
The defining metric of the entire allocation system is not dollars disbursed but health outcomes achieved: DALYs averted, infections prevented, and lives saved, measured against independent monitoring data and reported cumulatively across two decades of Global Fund operation.
Impact measurement combines routine program monitoring (treatment coverage, case notification, commodity distribution reported by implementing countries) with independent modeling that translates coverage into estimated health outcomes averted — the same epidemiological modeling infrastructure (UNAIDS Spectrum, WHO TB burden models, malaria transmission models) used to estimate burden in Stage 1 is run again, this time comparing observed program coverage against a modeled counterfactual of no intervention.
The headline figure — roughly 59 million lives saved cumulatively since the Global Fund's founding in 2002, cited in recent replenishment materials — is the product of this counterfactual modeling applied across the full multi-decade grant portfolio, not a direct headcount, and is independently reviewed by the Fund's Technical Evaluation Reference Group to guard against attribution inflation.
Cost-effectiveness is expressed as cost per DALY averted, which varies substantially by disease and delivery context: insecticide-treated bednet distribution for malaria prevention is typically among the most cost-effective interventions in global health (often well under $100 per DALY averted), while second-line multidrug-resistant TB treatment is markedly more expensive per DALY due to longer treatment courses and more costly drugs.
The Global Fund's replenishment materials report that its investments have contributed to a roughly 61% combined reduction in HIV, TB, and malaria deaths since 2002 in the countries where it invests — the single figure donor governments cite most often when justifying continued replenishment funding at the multi-billion-dollar scale.
Impact data is not a retrospective scorecard alone — it is a direct input into the next replenishment cycle's political case (donors fund what demonstrably works) and into Stage 6's within-cycle reallocation decisions, closing the loop between the formula that opened this simulation and the outcomes it was designed to produce.
Allocation is not fixed for the full three-year cycle once signed. Grants rated as underperforming, or facing absorption or fiduciary problems, can have unspent funds reprogrammed toward higher-performing programs or higher-burden needs elsewhere in the portfolio — a performance feedback loop layered on top of the initial needs-based formula.
Every active grant is continuously rated by the Secretariat's Grant Management teams on programmatic and financial performance. A grant that repeatedly misses agreed targets, shows weak financial absorption, or triggers a fiduciary risk finding (from Office of the Inspector General audits or in-country reviews) moves onto a corrective action plan; if performance does not recover, disbursement of subsequent tranches is paused and the unspent envelope becomes eligible for reprogramming.
Reprogrammed funds are redirected through the same needs-based logic that governed the original allocation — toward programs in the same country with a stronger delivery track record, toward under-resourced high-burden interventions within the same disease portfolio, or in some cases toward a different country entirely if in-country absorptive capacity cannot be restored within the remaining cycle.
This mechanism converts the allocation formula from a one-time, front-loaded calculation into a continuously adjusted system — the simulation's flagged, redirected flow stream is a direct visualization of this within-cycle performance correction.
Alongside country-envelope reallocation, the Global Fund reserves a portion of each replenishment — termed catalytic investments — for cross-cutting priorities that a strict burden-and-income formula would under-fund: health systems strengthening, community and human-rights systems, pandemic preparedness, and programs targeting key populations disproportionately affected by HIV but politically or socially marginalized within their own countries.
This set-aside functions as a deliberate correction to the limits of a purely quantitative formula — burden and income data can miss structural barriers to access (stigma, discriminatory laws, weak community health infrastructure) that no DALY estimate captures directly, so catalytic funding is allocated through a separate, more qualitative review process layered on top of the country-envelope mechanics covered in Stages 1–2.